Advances in Treatment for Retinal Disease: What Optometrists Need to Know: Long-Acting Treatment Options for nAMD and DME
Activity Description and Purpose
This is Part 3 of a 4-part series of 15-minute discussions that will help optometrists who care for patients with neovascular age-related macular degeneration and diabetic macular edema better understand how to address the burden patients face, current treatment options, the need for longer-acting treatments, and best practices. This module is accredited for 0.25 COPE CE credit.
This educational activity is intended for optometrists.
- Describe efficacy/safety data on treatment with extended-release anti–vascular endothelial growth factor for neovascular age-related macular degeneration
Mohammad Rafieetary, OD, FAAO, FORS
Arshad M. Khanani, MD, MA, FASRS
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Arshad M. Khanani, MD, MA, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch & Lomb Incorporated, Broadwing Bio, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Cholgene Therapeutics Inc,
F. Hoffmann-La Roche Ltd, 4DMT, Gemini Therapeutics, Genentech, Inc, Graybug, Inc, Gyroscope, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kato Pharmaceuticals, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Oculis, Opthea, Oxurion NV, PolyPhotonix, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Retrotope Inc*, Thea Pharmaceuticals Limited, and Unity Biotechnology; is on the speakers bureau for Allergan, Genentech, Inc, and Novartis Pharmaceuticals Corporation; is a contracted researcher for Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, 4DMT, Gemini Therapeutics, Genentech, Inc, Gyroscope, Iveric Bio, Inc, Kodiak Sciences Inc, NGM Bio, Novartis Pharmaceuticals Corporation, Oculis, Opthea, Oxurion NV, Regenxbio Inc, and Unity Biotechnology; and has stock options in Aviceda Therapeutics, PolyPhotonix, and Retrotope Inc*.
Mohammad Rafieetary, OD, is an advisory board member of Apellis Pharmaceuticals, Cardinal Health, Heidelberg Engineering GmbH, Iveric Bio, Inc, Notal Vision, Optos, and Regeneron Pharmaceuticals, Inc; and is on the speakers bureau for Heidelberg Engineering GmbH, Notal Vision, Optos, Regeneron Pharmaceuticals, Inc, and Spark Therapeutics, Inc.
* The financial relationship existed during the last 24 months but has now ended
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
COPE approved for 0.25 CE credit for optometrists.
COPE Course ID: 82144-TD
COPE Course Category: Treatment & Management of Ocular Disease
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Genentech, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.
This CE activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 282.3
- 0.25 COPE